Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn:
“New HER2DX Data at SABCS 2025
REVEAL GENOMICS has presented new results across seven HER2DX abstracts, covering more than 1,300 tumors in HER2-positive breast cancer.
One of the highlights is the new CNS Progression Score, which identifies individuals at higher risk of developing brain metastases in advanced disease. The model clearly separated risk groups, with 3-year CNS progression rates of:
- 39.2% in the high-risk group
- 13% in the intermediate-risk group
- 4.3% in the low-risk group
Other presentations confirmed the value of the HER2DX risk and pCR scores in early-stage disease and showed that TILs do not add predictive value for pCR once the HER2DX pCR score is considered. Overall, the data continue to support HER2DX as a robust genomic tool across the HER2-positive spectrum.
More posts from Aleix Prat.